as of 08-06-2026 3:46pm EST
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 22.4B | IPO Year: | 2000 |
| Target Price: | $201.17 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 24 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.82 | EPS Growth: | -15.26 |
| 52 Week Low/High: | $90.39 - $212.75 | Next Earning Date: | 05-07-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 182.31% | Revenue Growth (next year): | 65.19% |
| P/E Ratio: | -130.29 | Index: | |
| Free Cash Flow: | -967575000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chair and CEO
Avg Cost/Share
$106.03
Shares
10,700
Total Value
$1,134,890.32
Owned After
259,058
Chair and CEO
Avg Cost/Share
$117.56
Shares
10,699
Total Value
$1,256,084.13
Owned After
259,058
Chief Medical Officer
Avg Cost/Share
$109.81
Shares
12,302
Total Value
$1,352,931.88
Owned After
60,486
Chair and CEO
Avg Cost/Share
$104.25
Shares
21,398
Total Value
$2,210,762.94
Owned After
259,058
Chief Legal Officer
Avg Cost/Share
$95.82
Shares
1,806
Total Value
$173,050.92
Owned After
37,648
SEC Form 4
Chair and CEO
Avg Cost/Share
$94.03
Shares
6,515
Total Value
$612,605.45
Owned After
259,058
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$103.78
Shares
1,858
Total Value
$192,823.24
Owned After
60,486
SEC Form 4
Chair and CEO
Avg Cost/Share
$102.27
Shares
7,605
Total Value
$777,763.35
Owned After
259,058
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$102.27
Shares
2,566
Total Value
$262,424.82
Owned After
60,486
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$102.27
Shares
2,404
Total Value
$245,857.08
Owned After
69,082
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Lewis William | INSM | Chair and CEO | Jul 23, 2026 | Sell | $106.03 | 10,700 | $1,134,890.32 | 259,058 | |
| Lewis William | INSM | Chair and CEO | Jul 9, 2026 | Sell | $117.56 | 10,699 | $1,256,084.13 | 259,058 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Jul 6, 2026 | Sell | $109.81 | 12,302 | $1,352,931.88 | 60,486 | |
| Lewis William | INSM | Chair and CEO | Jun 25, 2026 | Sell | $104.25 | 21,398 | $2,210,762.94 | 259,058 | |
| Smith Michael Alexander | INSM | Chief Legal Officer | Jun 22, 2026 | Sell | $95.82 | 1,806 | $173,050.92 | 37,648 | |
| Lewis William | INSM | Chair and CEO | Jun 8, 2026 | Sell | $94.03 | 6,515 | $612,605.45 | 259,058 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Jun 5, 2026 | Sell | $103.78 | 1,858 | $192,823.24 | 60,486 | |
| Lewis William | INSM | Chair and CEO | Jun 3, 2026 | Sell | $102.27 | 7,605 | $777,763.35 | 259,058 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Jun 3, 2026 | Sell | $102.27 | 2,566 | $262,424.82 | 60,486 | |
| Bonstein Sara | INSM | Chief Financial Officer | Jun 3, 2026 | Sell | $102.27 | 2,404 | $245,857.08 | 69,082 |
SEC 8-K filings with transcript text
May 7, 2026 · 100% conf.
1D
+2.40%
$107.32
Act: -3.50%
5D
+5.78%
$110.86
Act: +10.32%
20D
+7.13%
$112.28
Act: -10.10%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.c706d217.1784333530.cc9f8351
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
Feb 19, 2026 · 99% conf.
1D
+2.39%
$164.84
Act: +2.43%
5D
+5.75%
$170.26
Act: -7.42%
20D
+7.09%
$172.42
false000110450600011045062026-02-172026-02-17
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 17, 2026
(Exact name of registrant as specified in its charter)
Virginia
000-30739
54-1972729
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
700 US Highway 202/206
Bridgewater, New Jersey
08807
(Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (908) 977-9900
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.01 per share
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Results of Operations and Financial Condition.
On February 19, 2026, Insmed Incorporated (the “Company”) issued a press release regarding its financial results for the three months and fiscal year ended December 31, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 pursuant to this Item 2.02. The slide presentation to be used during the conference call referenced in the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference.
The information contained herein, including the exhibits attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 17, 2026, David W.J. McGirr notified the board of directors (the “Board”) of the Company that he will not stand for re-election to the Board upon the expiration of his current term as a Class II director, which will occur at the Company’s 2026 Annual Meeting of Shareholders (the “Annual Meeting”). Mr. McGirr will continue to serve as a member of the Board and chair of the Audit Committee of the Board until the Annual Meeting. Mr. McGirr’s decision to not stand for re-election to the Board was not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
No.
Description
99.1
Press release issued by Insmed Incorporated on February 19, 2026.
99.2
Insmed Incorporated February 19, 2026 Presentation.
104
Cover Page Interactive Date File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 19, 2026
By:
/s/ Michael A. Smith
Name:
Michael A. Smith
Title:
Chief Legal Officer and Corporate Secretary
Oct 30, 2025
false000110450600011045062025-10-302025-10-30
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 30, 2025
(Exact name of registrant as specified in its charter)
Virginia
000-30739
54-1972729
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
700 US Highway 202/206
Bridgewater, New Jersey
08807
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (908) 977-9900
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Stock, par value $0.01 per share
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02 — Results of Operations and Financial Condition.
On October 30, 2025, Insmed Incorporated (the “Company”) issued a press release regarding its financial results for the third quarter ended September 30, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 pursuant to this Item 2.02 and is incorporated herein by reference. The slide presentation to be used during the conference call referenced in the press release is furnished herewith as Exhibit 99.2.
The information contained herein, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
ITEM 9.01 – Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No.
Description
99.1
Press release issued by Insmed Incorporated on October 30, 2025.
99.2
Insmed Incorporated October 30, 2025 Presentation.
104
Cover Page Interactive Date File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 30, 2025
By:
/s/ Michael A. Smith
Name:
Michael A. Smith
Title:
Chief Legal Officer and Corporate Secretary
See how INSM stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "INSM Insmed Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.